Abstract: The invention provides antimicrobial composition comprising (a) a first active ingredient, wherein in the first active ingredient is selected from the group consisting of petroleum jelly, EpiCeram® emulsion, and/or glycerin, and (b) a second active ingredient selected from the group consisting of 1-octanoyl-rac-glycerol, 1-decanoyl-rac-glycerol, glycerol monolaurate (GML), rac-glycerol 1-myrstate, glycerol monocaprate, glycerol monocaprylate, glycerol monomyristate, or reutericyclin, wherein the second active ingredient is present at a concentration of 10 ?g/ml to 100 mg/ml in the composition. The compositions are useful as antimicrobial agents.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: The present disclosure provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate combined with a required gel, and are administered topically, for example, to treat viral, fungal, bacterial, or protozoan infections.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: This disclosure describes the ability of glycerol monolaurate, formulated both as a solution and as a nonaqueous gel, to kill antimicrobial resistant C. auris. Additionally, this disclosure describes the ability of glycerol monolaurate formulated as a non-aqueous gel to kill clinically isolated Candida species.

Abstract: Disclosed are compositions and methods for treatment microbial infections. The compositions comprise glycerol monolaurate or a derivative thereof, and can be administered topically, for example, to treat gonorrhea and Zika.

Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Abstract: This invention relates to treating and preventing urinary tract infections. Glycerol monolaurate (GML) and/or GML-related compositions together with suitable accelerants in gel-based formulation may be used to treat urinary tract infections that may be generally diagnosed, for example, in women, catheterized patients and elderly individuals. Such a gel-based formulation kills, or inhibits the growth of, one or more pathogenic microorganisms that cause urinary tract infections.

Abstract: Methods of treating Otitis externa by inhibiting the growth of, or killing, certain microorganisms associated with this condition are disclosed. Prophylaxis methods of inhibiting Otitis externa infections are also disclosed.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Abstract: The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious microorganisms and inflammatory responses to infectious microorganisms or factors.

Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.

Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.